Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Core Viewpoint - Citius Pharmaceuticals Inc. has successfully closed a registered direct offering, raising approximately $6 million, with potential additional proceeds of up to $9.8 million from short-term warrants [1][3]. Group 1: Offering Details - The offering consisted of 4,920,000 shares of common stock priced at $1.22 per share, along with short-term warrants to purchase an additional 9,840,000 shares [1][3]. - The short-term warrants have an exercise price of $1.00 per share, are immediately exercisable, and will expire 24 months from the initial exercise date [1][3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support the commercial launch of LYMPHIR™, including milestone and regulatory payments, as well as general corporate purposes [3]. Group 3: Company Background - Citius Pharmaceuticals is focused on developing first-in-class critical care products, with LYMPHIR approved by the FDA for treating cutaneous T-cell lymphoma [6]. - The company also has a late-stage pipeline that includes Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief [6].